Harmony Biosciences recently released findings from the RECONNECT study, a clinical trial designed to test whether ZYN002, a cannabidiol (CBD) gel, was effective for some of the difficulties in fragile X syndrome. This was an international trial which included several sites in the UK, of which the Patrick Wild Centre was one. Unfortunately the study did not meet its primary endpoint – this means that ZYN002 was no better than placebo (a gel which doesn’t contain any active medicine) at improving social avoidance in people with fragile X syndrome.
More information will come out about the study fundings in due course and we will update participants and families when this happens.
We would like to thank the many people in the UK fragile X community who took part in this trial. Although the findings are disappointing, we have learned a lot which will help the development of new therapies in the future.
You can read the press release from Harmony Biosciences here:
